Palabras clave
Profilaxis pre-exposición
Servicios farmacêuticos
Atención farmacéutica
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Mapear las estrategias de Profilaxis Pre-Exposición (PrEP) al VIH en poblaciones de mayor vulnerabilidad e identificar el papel del farmacéutico en el acceso y la adherencia. Métodos: Revisión de alcance realizada según el Joanna Briggs Institute (JBI), utilizando el acrónimo PCC (Participantes: servicios de distribución/dispensación de PrEP; Concepto: PrEP al VIH; Contexto: poblaciones vulnerables). Se realizaron búsquedas en Lilacs, PubMed, SciELO, Cochrane, JBI Evidence Synthesis, ScienceDirect, CAPES y Google Académico, de 2021 a 2026. Los estudios fueron gestionados en Mendeley® y seleccionados en Rayyan®. Resultados: Se incluyeron 19 artículos. La mayoría presentó nivel de evidencia muy bajo (57,9%). Solo 3 estudios (15,7%) abordaron el papel del farmacéutico, evidenciando una brecha en la literatura. Los factores socioeconómicos, el estigma, la escolaridad y la raza fueron los principales determinantes para el acceso y la adherencia a la PrEP. Consideraciones finales: La PrEP es una estrategia efectiva, pero barreras estructurales y sociales limitan su alcance en poblaciones vulnerables. La actuación farmacéutica es prometedora, pero poco explorada, requiriendo estudios más robustos y políticas públicas inclusivas.
Referencias
ALEXANDRE HO, et al. HIV pre-exposure prophylaxis in Latin America: public policies, healthcare systems and human rights. Prev Med Rep, 2025; 54: 103070.
AROMATARIS E, MUNN Z, editors. JBI manual for evidence synthesis [Internet]. Adelaide: JBI; 2020.
CAMBIANO V, et al. The effect of combination prevention strategies on HIV incidence among gay and bisexual men who have sex with men in the UK: a model-based analysis. Lancet HIV, 2023; 10(11): e713-e722.
CHAVES JC, et al. Intervenções farmacêuticas e seus desfechos em portadores de HIV/AIDS em atendimento de média complexidade. Rev Eletron Acervo Saude, 2021; 13(4): e4390.
CORDEIRO L, SOARES CB. Revisão de escopo: potencialidades para a síntese de metodologias utilizadas em pesquisa primária qualitativa. BIS, Bol Inst Saúde, 2019; (Número Especial): 37-42.
CRAWFORD ND, et al. Feasibility of reaching populations at high risk for HIV in community pharmacies. J Am Pharm Assoc (2003), 2024; 64(6): 102239.
CRITICAL APPRAISAL SKILLS PROGRAMME. CASP checklist: 10 questions to help you make sense of qualitative research [Internet]. Oxford: CASP; 2018.
GAN YN, et al. Development and evaluation of an online HIV pre-exposure prophylaxis (PrEP) training program for community pharmacists to implement pharmacy-led PrEP services in Malaysia. PLoS One, 2025; 20(8): e0328713.
HARRISON C, et al. Qualitative exploration of the barriers and facilitators to community pharmacy PrEP delivery for UK pharmacists and underserved community members using the COM-B model of behaviour change. Sex Transm Infect, 2024; 100: 1-8.
HAYNES AS, et al. A systematic review and narrative synthesis of factors affecting pre-exposure prophylaxis willingness among Black women for HIV prevention. AIDS Behav, 2025; 29: 101-132.
HUDRUDCHAI S, et al. Pre-exposure prophylaxis adherence among men who have sex with men: a systematic review and meta-analysis. J Prev Med Public Health, 2024; 57: 8-17.
JAISWAL J, et al. PrEP-related medical, structural and institutional mistrust among a socioeconomically diverse sample of Black, Latine, Asian, and White young sexual minority men: lived experiences of intersectional inequity. AIDS Behav, 2026; 30: 440-453.
JALIL EM, et al. Low PrEP adherence despite high retention among transgender women in Brazil: the PrEParadas study. J Int AIDS Soc, 2022; 25: e25896.
MARCUS U, et al. Analysis of HIV pre-exposure prophylaxis (PrEP) needs and PrEP use in Germany among men who have sex with men. J Public Health, 2022; [volume e páginas a definir – verifique na publicação final].
MINISTÉRIO DA SAÚDE (BR). Relatório de implantação PrEP HIV: jan-dez 2018. Brasília, DF: Ministério da Saúde; 2019.
MINISTÉRIO DA SAÚDE (BR). Boletim epidemiológico HIV/Aids 2024: número especial. Brasília, DF: Ministério da Saúde; 2024.
MINISTÉRIO DA SAÚDE (BR). Secretaria de Vigilância em Saúde. Protocolo clínico e diretrizes terapêuticas para profilaxia pré-exposição (PrEP) de risco à infecção pelo HIV, infecções sexualmente transmissíveis e hepatites virais. Brasília, DF: Ministério da Saúde; 2025.
MINISTÉRIO DA SAÚDE (BR). Sistema de Controle Logístico de Medicamentos (SICLOM) [Internet]. Brasília, DF: Ministério da Saúde; 2025. Disponível em: https://siclom.aids.gov.br/. Acesso em: 23 maio 2026.
MONTEIRO, PVA, et al. Uso da profilaxia pré-exposição ao HIV entre homens gays e outros homens que fazem sexo com homens.. Escola Anna Nery, 2024; 28: e20240093, 2024.
MURAD MH, et al. New evidence pyramid. Evid Based Med, 2016; 21(4): 125-127.
OMENOBA TC, et al. Expanding HIV prevention: exploring community pharmacists' willingness to provide PrEP in Nigeria. AIDS Behav, 2026; 30: 778-787.
O'NEILL J, et al. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. J Clin Epidemiol, 2014; 67(1): 56-64.
PETERS MDJ, et al. Scoping reviews. In: AROMATARIS E, MUNN Z, editors. JBI manual for evidence synthesis [Internet]. Adelaide: JBI; 2024.
SEPODES B, et al. Implementation and access to pre-exposure prophylaxis for human immunodeficiency virus by men who have sex with men in Europe. Front Med, 2021; 8: 722247.
SIQUEIRA CG, et al. Rastreamento de infecções sexualmente transmissíveis em pessoas não grávidas assintomáticas pertencentes a populações mais vulnerabilizadas: uma revisão de escopo rápida. Rev Panam Salud Publica, 2025; 49: e113.
SKOVDAL M, et al. Improving access to pre-exposure prophylaxis for adolescent girls and young women: recommendations from healthcare providers in eastern Zimbabwe. BMC Infect Dis, 2022; 22: 399.
SULLIVAN PS, et al. Estimating HIV incident diagnoses among men who have sex with men eligible for pre-exposure prophylaxis but not taking it: protocol and feasibility assessment of data sources and methods. JMIR Res Protoc, 2023; 12: e42267.
TIGUMAN GMB, et al. Role of pharmacists in HIV prophylaxis: a scoping review of pharmacists' services, interventions and outcomes. J Int AIDS Soc, 2026; 29: e70090.
TRICCO AC, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med, 2018; 169(7): 467-473.
VAN DEN ELSHOUT MAM, et al. Sexual behaviour and incidence of sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis (PrEP): four-year follow-up of the Amsterdam PrEP demonstration project cohort. PLoS Med, 2024; 21(5): e1004328.